{"name":"jiangjingting","slug":"jiangjingting","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IL-2 pre-treated CD19 cells","genericName":"IL-2 pre-treated CD19 cells","slug":"il-2-pre-treated-cd19-cells","indication":"B-cell malignancies expressing CD19","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IL-7/IL-15 pre-treated CD19 cells","genericName":"IL-7/IL-15 pre-treated CD19 cells","slug":"il-7-il-15-pre-treated-cd19-cells","indication":"B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma)","status":"marketed"}]}],"pipeline":[{"name":"IL-2 pre-treated CD19 cells","genericName":"IL-2 pre-treated CD19 cells","slug":"il-2-pre-treated-cd19-cells","phase":"marketed","mechanism":"IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity.","indications":["B-cell malignancies expressing CD19"],"catalyst":""},{"name":"IL-7/IL-15 pre-treated CD19 cells","genericName":"IL-7/IL-15 pre-treated CD19 cells","slug":"il-7-il-15-pre-treated-cd19-cells","phase":"marketed","mechanism":"IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.","indications":["B-cell malignancies expressing CD19 (e.g., acute lymphoblastic leukemia, diffuse large B-cell lymphoma)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}